Sveriges mest populära poddar
BiotechTV - News

BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed

12 min1 april 2025

He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it for conditions like the surfactant protein deficiencies SP-B & ABCA3, alpha-1 antitrypsin deficiency, and IPF.

BiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.